Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CANTOS canakinumab trial in stable post-myocardial infarction patients with elevated hsCRP
NL-OMON35757Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Sep 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myocardial infarction (MI), atherosclerotic disease and type 2 diabetes mellitus (T2DM) comparing Canakinumab with Placebo (2 arms). Primary endpoint: Primary composite cardiovascular endpoint. Started Sep 2011; status: active, not recruiting.
02
Drugs
canakinumab
03
Conditions
myocardial infarction (MI)atherosclerotic diseasetype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON35757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35757.